Mohiuddin Mohammed, Park Rex, Wesselmann Ursula, Pukall Caroline, Jarvi Keith, Nickel Curtis, Doiron Christopher, Gilron Ian
Department of Anesthesiology & Perioperative Medicine, Kingston General Hospital, Queen's University, Kingston, ON, Canada.
Departments of Anesthesiology and Perioperative Medicine, Division of Pain Medicine, Neurology and Psychology, The University of Alabama at Birmingham, Birmingham, AL, United States.
JMIR Res Protoc. 2021 May 17;10(5):e21909. doi: 10.2196/21909.
Chronic pelvic pain with various etiologies and mechanisms affects men and women and is a major challenge. Monotherapy is often unsuccessful for chronic pelvic pain, and combinations of different classes of medications are frequently prescribed, with the expectation of improved outcomes. Although a number of combination trials for chronic pelvic pain have been reported, we are not aware of any systematic reviews of the available evidence on combination drug therapy for chronic pelvic pain.
We have developed a protocol for a systematic review to evaluate available evidence of the efficacy and safety of drug combinations for chronic pelvic pain.
This systematic review will involve a detailed search of randomized controlled trials investigating drug combinations to treat chronic pelvic pain in adults. The databases searched will include the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from their inception until the date the searches are run to identify relevant studies. The primary outcome will be pain relief measured using validated scoring tools. Secondary outcomes, where reported, will include the following: adverse events, serious adverse events, sexual function, quality of life, and depression and anxiety. Methodological quality of each included study will be assessed using the Cochrane Risk of Bias Tool.
The systematic review defined by this protocol is expected to synthesize available good quality evidence on combination drug therapy in chronic pelvic pain, which may help guide future research and treatment choices for patients and their health care providers.
This review will provide a clearer understanding of the efficacy and safety of combination pharmacological therapy for chronic pelvic pain.
PROSPERO International Prospective Register of Systematic Reviews CRD42020192231; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192231.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/21909.
各种病因和机制导致的慢性盆腔疼痛影响着男性和女性，是一项重大挑战。单一疗法治疗慢性盆腔疼痛往往不成功，因此常常开具不同种类药物的联合处方，期望能改善治疗效果。尽管已经报道了一些针对慢性盆腔疼痛的联合治疗试验，但我们尚未发现对慢性盆腔疼痛联合药物治疗现有证据的任何系统评价。
我们制定了一项系统评价方案，以评估慢性盆腔疼痛联合药物治疗有效性和安全性的现有证据。
这项系统评价将详细检索调查联合药物治疗成人慢性盆腔疼痛的随机对照试验。检索的数据库将包括Cochrane对照试验中心注册库（CENTRAL）、MEDLINE和EMBASE，从其创建之日起至检索执行之日，以识别相关研究。主要结局将使用经过验证的评分工具测量疼痛缓解情况。如有报告，次要结局将包括以下内容：不良事件、严重不良事件、性功能、生活质量以及抑郁和焦虑。每项纳入研究的方法学质量将使用Cochrane偏倚风险工具进行评估。
本方案定义的系统评价预计将综合慢性盆腔疼痛联合药物治疗的现有高质量证据，这可能有助于指导患者及其医疗服务提供者未来的研究和治疗选择。
本评价将更清楚地了解慢性盆腔疼痛联合药物治疗的有效性和安全性。
PROSPERO国际前瞻性系统评价注册库CRD42020192231；https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192231。
国际注册报告识别号（IRRID）：PRR1-10.2196/21909。
